Valsacor comp. is commonly used across conditions presenting with systemic or localized discomfort, specifically hypertension. The goal of blood pressure control is to address the risk of serious complications, which is the primary long-term therapeutic benefit. Lowering blood pressure contributes to a reduced risk of cardiovascular events.

---

Therapeutic Scope and Benefits

This combination is commonly used across conditions presenting with systemic or localized discomfort, such as essential hypertension. It is generally used in clinical situations where high blood pressure is uncontrolled by monotherapy or when patients exhibit more significant pressure elevations who may require multiple agents. This medication assists with managing symptoms related to systemic imbalance, which helps improve day-to-day comfort during symptomatic periods.

For patients whose condition is resistant to single-drug regimens, this dual-agent tablet is often used during phases when symptoms become more noticeable and supportive relief is needed. The long-term support plays a role in managing symptoms that create noticeable physiological strain on the heart and arteries, which helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact: Relief for Elevated Arterial Pressure

Valsacor comp. is commonly used to help with managing the risk associated with sustained high blood pressure, providing supportive relief that assists with maintaining functional stability.

Regulatory References

1. DailyMed official US drug label for Valsartan and Hydrochlorothiazide

Eligibility Map: Who can and cannot use Valsacor comp.

Regulatory documents establish strict eligibility criteria for the use of Valsartan/Hydrochlorothiazide combination (Valsacor comp.), defining specific populations who are permitted, restricted, or prohibited from using the medicine.

Eligibility Status Summary

Classification	Population/Condition
Absolutely Contraindicated	Pregnancy (second and third trimesters) or planned pregnancy, Anuria, Severe Renal Impairment (CrCl < 30 mL/min), Severe Hepatic Impairment, and Hypersensitivity to the drug or sulfonamide derivatives.
Not Recommended	The Pediatric population (under 18 years) due to unestablished safety and efficacy. Use in Breastfeeding is also not recommended, requiring discontinuation of the drug or nursing.
Conditional Use/Caution	Patients with pre-existing Volume- and/or Salt-Depletion must have this condition corrected prior to administration. Caution is also necessary for patients with a history of Angioedema or those with Mild to Moderate Hepatic Impairment.

This medication is officially indicated for Adults with hypertension, particularly when blood pressure is not adequately controlled on monotherapy. The regulatory profile sets mandatory exclusions based on physiological status, age, and pre-existing severe organ dysfunction.

The official regulatory profile for Valsacor comp. details specific interaction patterns, primarily categorized by pharmacodynamic and pharmacokinetic mechanisms.

Contraindicated Combinations

A strict contraindication is documented for the co-administration of Aliskiren with Valsacor comp. in patients with diabetes mellitus or with renal impairment (GFR < 60 mL/min/1.73 m²) due to the increased risks of hyperkalemia, hypotension, and worsening renal function. This restriction addresses the formal prohibition of dual Renin-Angiotensin-System (RAS) blockade in specific populations.

---

Other Clinically Significant Interactions

Interacting Product Category	Officially Documented Interaction Outcome
Ion Exchange Resins (e.g., Cholestyramine, Colestipol)	Reduced absorption of the Hydrochlorothiazide component. A mandatory timing separation is required, specifying administration at least 4 hours before or 4 to 6 hours after the resin.
Lithium	Increased serum concentrations and risk of toxicity due to reduced renal clearance.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)	Reduced antihypertensive effect and increased risk of renal impairment, officially noted as heightened in elderly patients.
Potassium Supplements / Spreading Diuretics	Risk of hyperkalemia (high serum potassium levels).
Alcohol, Barbiturates, Narcotics	Potentiation of orthostatic hypotension (additive hypotensive effect).

The drug's interaction structure, as defined in regulatory documents, explicitly categorizes combinations that are prohibited and outlines necessary timing constraints for co-administration.

Valsacor comp. acts via a dual mechanism.

Valsartan: AT1 Receptor Antagonism

Valsartan, an Angiotensin II Type 1 Receptor Blocker ( AT1 ARB), selectively binds to and antagonizes the AT1 receptor. This blockade prevents the activity of endogenous Angiotensin II, thereby inhibiting AT1-mediated vasoconstriction, aldosterone release from the adrenal cortex, and renal sodium reabsorption. This action modulates the Renin-Angiotensin-Aldosterone System (RAAS) and leads to reduced systemic vascular resistance and a decrease in cardiac wall tension.

Hydrochlorothiazide: Renal Ion Transport Inhibition

Hydrochlorothiazide, a diuretic component, inhibits the sodium chloride cotransporter ( NCC) in the distal convoluted tubule of the kidney. This enzyme inhibition decreases the reabsorption of sodium and chloride ions. The consequence is a concomitant increase in the urinary excretion of water, sodium, and chloride, resulting in a reduction of circulating plasma volume.

Valsacor comp. is administered orally as a film-coated tablet and is intended for once-daily use.

---

Administration Scope

Instruction	Detail
Route and Form	Oral; must be swallowed whole and should not be crushed or chewed.
Standard Dosing	The initial dose is commonly 160 mg Valsartan / 12.5 mg Hydrochlorothiazide once daily. The maximum daily dose is 320 mg Valsartan / 25 mg Hydrochlorothiazide.
Timing	Can be taken with or without food. Administration in the morning is generally suggested due to the diuretic component.
Dose Titration	Dosage adjustments should only occur after 1 to 2 weeks of therapy, as the full effect of a dose change requires time to manifest.

---

Population Constraints and Procedural Rules

There are specific instructions for certain patient populations and general procedural rules for daily administration.

For patients with mild to moderate hepatic impairment, the valsartan component dose should not exceed 80 mg. Use is also generally not recommended for patients with severe renal impairment (Creatinine Clearance < 30 mL/min), and the product is not recommended for patients under 18 years of age. If a dose is missed, it should be skipped if it is near the time for the next scheduled dose; doses must not be doubled. This procedural structure is designed to maintain a consistent treatment approach.

Research Evidence for Managing High Blood Pressure

The research for Valsacor comp. (Valsartan/Hydrochlorothiazide) was studied for outcomes related to monitoring physiological strain or stress, primarily focusing on high blood pressure. These studies were evaluated in adults with essential hypertension using short-term Randomized Controlled Trials (RCTs), where participants was observed in controlled settings. The primary outcomes measured in these trials were changes in sitting systolic and diastolic blood pressure (SBP and DBP).

Findings describe patterns observed in the studies where the concurrent administration of both agents data show patterns related to distinct measurements of blood pressure change compared to the measurements observed when either Valsartan or Hydrochlorothiazide was studied for use as a single agent. Research highlights changes measured during the study period, with findings indicating patterns related to the measured blood pressure changes.

Studies in Specific Adult Patient Groups

Research examined outcomes related to systemic or functional imbalance across various adult populations. For the elderly (adults aged 70 years and older), studies have explored the measurements of blood pressure change, and findings indicate patterns consistent with those seen in the general adult population. Research describes studies involving patients with high blood pressure and other co-occurring conditions, such as diabetes, where investigators monitored measurements related to vascular function.

Research Gaps and Areas of Uncertainty

The research record includes intermediate-term observational studies, where participants was observed in settings evaluating daily-life functioning for periods extending up to 54 weeks. Concerning long-term effects, the data are still emerging, and long-term effects are not fully established by trials designed specifically for the fixed-dose combination. The examination of the risk of major cardiovascular events is derived from the evidence base for the individual drug classes (Angiotensin II Receptor Blockers and Thiazide Diuretics). Data for certain groups remain insufficient as the pediatric population was not studied for this combination.

Key Studies & References

1. DailyMed - Valsartan and Hydrochlorothiazide tablet, film coated (Official Drug Label)

Common questions about Valsacor comp. (FAQ)

Q: Is Valsacor comp. intended for short-term or long-term use?

A: Official product information describes this medicine as being designated for the long-term or chronic management of high blood pressure. This designation is consistent with the need for ongoing use to maintain blood pressure control.

Q: What does the 'comp.' part of the drug name signify?

A: The 'comp.' in the trade name is a common abbreviation used in pharmacy and regulatory contexts to indicate that the product is a fixed-dose combination. This means the tablet contains two different active ingredients in one pill.

Q: How does Valsacor comp. differ from an ACE inhibitor-based combination medicine?

A: Valsacor comp. works by blocking the Angiotensin II receptor, which prevents the substance Angiotensin II from acting on blood vessels. In contrast, an ACE inhibitor works by blocking the enzyme responsible for creating Angiotensin II. They represent different mechanistic approaches to managing the body's Renin-Angiotensin System.

Q: What official resources provide reliable, non-commercial patient information on Valsacor comp.?

A: Official, non-commercial sources for reliable patient information include government health portals like MedlinePlus (from the NIH) and the patient information leaflets or summaries provided by major regulatory agencies. These sources focus on factual, non-promotional information.

Q: How quickly does Valsacor comp. usually start to affect blood pressure?

A: Official product information states that blood pressure typically begins to decrease during the first 2 weeks of treatment. The full measured benefit of the medicine may be observed after up to 4 weeks.

Q: Is it necessary to take Valsacor comp. at the exact same time every day?

A: Official guidelines suggest taking the medicine at around the same time every day. This practice helps maintain consistent therapeutic concentrations of the medicine.

Q: Are there official warnings about suddenly stopping the use of Valsacor comp.?

A: Regulatory information describes this medicine as intended for the chronic control of blood pressure. The official patient information emphasizes the importance of continuing to use the medication as directed for ongoing blood pressure management.

Q: Is it common to feel dizzy or tired when first starting Valsacor comp.?

A: Dizziness or lightheadedness is listed as a common side effect. Official patient information indicates that such effects may be more frequent when treatment is initially started.

Q: Are there specific symptoms that warrant immediate reporting to a healthcare provider?

A: Official documentation highlights specific severe or serious adverse reactions. These reactions include swelling of the face, tongue, or throat (angioedema), difficulty breathing, or severe changes in vision.

Q: Does Valsacor comp. cause a persistent cough like some other blood pressure medicines?

A: Cough is listed as a potential side effect in the official product information for this medicine.

Q: Is the medication described in official documents as causing insomnia?

A: Difficulty sleeping or insomnia has been listed as a potential, though often less common, side effect of the medicine.

Q: Is sun sensitivity a reported side effect of Valsacor comp.'s components?

A: Increased sensitivity to sunlight (photosensitivity) is listed as a potential, typically rare, side effect due to the diuretic component, Hydrochlorothiazide.

Q: What should be known about the safety classification for operating heavy machinery while using Valsacor comp.?

A: Official warnings note the potential for dizziness or fatigue. Individuals performing activities that require full mental alertness, such as driving or operating heavy machinery, should be aware of this potential effect.

Q: Does Valsacor comp. affect blood sugar or cholesterol levels?

A: The medicine may affect blood sugar levels, and high cholesterol or triglyceride levels have been reported as having occurred during use.

Q: Does this medicine have any known effects on uric acid levels?

A: The diuretic component (Hydrochlorothiazide) has been shown to cause an increase in uric acid levels in the blood.

Q: What is the drug's classification regarding its effects on potassium levels?

A: The medicine has a dual effect on potassium: it can cause hypokalemia (low potassium) due to the diuretic component but also carries a risk of hyperkalemia (high potassium) when combined with certain other agents or supplements.

Q: Are regular blood tests required for people using Valsacor comp.?

A: Official product information describes the periodic monitoring of renal function and potassium levels for patients, particularly those considered susceptible.

Q: Does Valsacor comp. require any special dietary restrictions like avoiding potassium-rich foods?

A: Official regulatory information states that due to the potential for the medicine to affect potassium levels, the co-administration of potassium supplements or salt substitutes is a monitored interaction because of the risk of high potassium.

Q: Can Valsacor comp. be used if a person has a history of gout?

A: Official patient information indicates that caution is required for use in patients with a history of gout or unusually high uric acid levels, due to the effect of the diuretic component.

Q: Is Valsacor comp. generally approved for use in elderly patients?

A: Clinical studies, which were reviewed by regulatory bodies, included elderly patients (70 years and older). The measurements of blood pressure change observed in these groups were consistent with the patterns seen in the general adult population.

Q: Does Valsacor comp. contain any ingredients that might be unsuitable for people with lactose intolerance?

A: Regulatory documents indicate that some formulations of this medicine may contain inactive ingredients like lactose. This is listed as a consideration for patients with rare hereditary conditions such as galactose intolerance.

Q: What type of research focuses on the long-term cardiovascular outcomes of Valsacor comp.?

A: Official regulatory documents state that information regarding the long-term risk of major cardiovascular events is primarily derived from the established evidence base for the individual drug classes (Angiotensin II Receptor Blockers and Thiazide Diuretics).

Q: What is the maximum duration of use reported in long-term studies for Valsacor comp.?

A: Intermediate-term observational studies for the fixed-dose combination have followed participants for periods extending up to 54 weeks.

Valsacor comp. (valsartan/hydrochlorothiazide) tablets must be stored according to regulatory requirements to ensure product stability and safety.

Storage & Disposal Scope

Labeled Storage Temperature Requirements:	Store at room temperature (20 C to 25 C / 68 F to 77 F) and away from excess heat.
Light/Moisture Protection Requirements:	Store away from excess moisture and away from direct light.
Handling Requirements:	Keep from freezing.
Packaging-related Storage Rules:	Keep medication in the original container, tightly closed.
Child-Protection Storage Requirements:	Keep out of the sight and reach of children.
Disposal Instructions (as documented in government sources):	Must not be thrown away via wastewater or household waste; dispose of according to local regulations.

Connection to the overall storage/disposal profile

Official regulatory documents define the required environment as room temperature, protected from freezing, heat, moisture, and light. Handling is restricted to storage in the original, tightly closed container. Disposal must follow pharmaceutical waste protocols, excluding household trash and wastewater, to adhere to environmental protection standards.